Global Temporal Arteritis Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Temporal Arteritis Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Temporal arteritis is also known as Horton's arteritis and is considered to be a severe form of vasculitis which means inflammation of the blood vessels. It is a potentially life-threatening inflammatory condition of the arteries. It can cause scalp tenderness and headaches. This condition usually occurs in temporal arteries and may occur in any medium to large artery of the body. As this condition generally occurs in aged population, it is also known as arteritis of the aged. Other names of temporal arteritis includes Horton disease, arteritis cranialis, and granulomatous arteritis.
Temporal Arteritis report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Temporal Arteritis market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital and Home Care are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Temporal Arteritis industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Temporal Arteritis key manufacturers include Novartis AG, Endo International Inc, Teva Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Cipla Inc, Dr Reddy's Laboratories Ltd, Abbott, F. Hoffmann -La Roche Ltd and Pfizer Inc, etc. Novartis AG, Endo International Inc, Teva Pharmaceutical Industries Ltd are top 3 players and held % sales share in total in 2022.
Temporal Arteritis can be divided into Oral and Parenteral, etc. Oral is the mainstream product in the market, accounting for % sales share globally in 2022.
Temporal Arteritis is widely used in various fields, such as Hospital, Home Care and Other,, etc. Hospital provides greatest supports to the Temporal Arteritis industry development. In 2022, global % sales of Temporal Arteritis went into Hospital filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Temporal Arteritis market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Novartis AG
Endo International Inc
Teva Pharmaceutical Industries Ltd
Glenmark Pharmaceuticals Ltd
Cipla Inc
Dr Reddy's Laboratories Ltd
Abbott
F. Hoffmann -La Roche Ltd
Pfizer Inc
Zydus Group
Lupin
Amorphex Therapeutics Holdings, Inc
Bausch Health Companies Inc
Regeneron Pharmaceuticals Inc
Astellas Pharma Inc
Segment by Type
Oral
Parenteral
Hospital
Home Care
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Temporal Arteritis market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Temporal Arteritis, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Temporal Arteritis industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Temporal Arteritis in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Temporal Arteritis introduction, etc. Temporal Arteritis Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Temporal Arteritis market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Temporal Arteritis report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Temporal Arteritis market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital and Home Care are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Temporal Arteritis industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Temporal Arteritis key manufacturers include Novartis AG, Endo International Inc, Teva Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Cipla Inc, Dr Reddy's Laboratories Ltd, Abbott, F. Hoffmann -La Roche Ltd and Pfizer Inc, etc. Novartis AG, Endo International Inc, Teva Pharmaceutical Industries Ltd are top 3 players and held % sales share in total in 2022.
Temporal Arteritis can be divided into Oral and Parenteral, etc. Oral is the mainstream product in the market, accounting for % sales share globally in 2022.
Temporal Arteritis is widely used in various fields, such as Hospital, Home Care and Other,, etc. Hospital provides greatest supports to the Temporal Arteritis industry development. In 2022, global % sales of Temporal Arteritis went into Hospital filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Temporal Arteritis market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novartis AG
Endo International Inc
Teva Pharmaceutical Industries Ltd
Glenmark Pharmaceuticals Ltd
Cipla Inc
Dr Reddy's Laboratories Ltd
Abbott
F. Hoffmann -La Roche Ltd
Pfizer Inc
Zydus Group
Lupin
Amorphex Therapeutics Holdings, Inc
Bausch Health Companies Inc
Regeneron Pharmaceuticals Inc
Astellas Pharma Inc
Segment by Type
Oral
Parenteral
Segment by Application
Hospital
Home Care
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Temporal Arteritis market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Temporal Arteritis, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Temporal Arteritis industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Temporal Arteritis in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Temporal Arteritis introduction, etc. Temporal Arteritis Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Temporal Arteritis market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices